FIG 5.
Galectin-3 was a target of miR-335. (A) The putative binding site between miR-335 and Galectin-3 was predicted by Targetscan. (B) HL-1 cells were cotransfected with miR-335 mimics or miR-NC, and the relative luciferase reporter activity of Gal-3 WT and Gal-3 MUT was measured by the dual-luciferase reporter system. (C) HL-1 cells were transfected with miR-335 mimics or miR-NC, and the protein expression of galectin-3 was detected by Western blotting. (D) HL-1 cells were transfected with sh-SNHG20, pc-SNHG20, and corresponding negative controls, and the protein expression of galectin-3 was detected by Western blotting. (E) HL-1 cells were cotransfected with pc-SNHG20 or pc-vector, and the relative luciferase reporter activity of Gal-3 WT and Gal-3 MUT was measured by the dual-luciferase reporter system. (F) The protein expression of galectin-3 in heart tissues of Ang II-treated mice or normal mice was detected by Western blotting. (G) HL-1 cells were treated with 10−6 M Ang II for different times (2, 4, 6, 8, 12, and 24 h), and the expression of galectin-3 was detected by Western blotting. (H) HL-1 cells were treated with different concentrations of Ang II (10−9, 10−8, 10−7, 10−6, and 10−5 M) for 24 h, and the expression of galectin-3 was detected by Western blotting. Each experiment was repeated three times. *, P < 0.05.